Monthly statement of total voting rights and shares
forming the company’s share capital

Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)



Market: Euronext Paris, Compartment C
ISIN code: FR0012616852



Total voting rights
Date Number of shares outstanding
Total gross (1) Total net (2)

November 30, 2025 34 931 012 44 816 425 44 600 800



(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In
accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to
which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into
account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly
informed, in accordance with the recommendation made by the AMF on 17 July 2007.


About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there
is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics
through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is
committed to radically improving treatment outcomes in sepsis and critical care.




Contact :

ABIONYX Pharma

infos@abionyx.com




1/1